Clinical Trial Detail

NCT ID NCT03785925
Title A Randomized Study of NKTR-214 Plus Nivolumab and of Reference Chemotherapy in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer With Low PD-L1 Expression (PIVOT-10)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nektar Therapeutics
Indications

transitional cell carcinoma

Therapies

Nivolumab + NKTR-214

Carboplatin + Gemcitabine

Age Groups: adult senior

No variant requirements are available.